BidaskClub upgraded shares of Regenxbio (NASDAQ:RGNX) from a hold rating to a buy rating in a research note released on Thursday.

A number of other analysts also recently issued reports on the company. Chardan Capital reaffirmed a buy rating and set a $75.00 price target (up from $55.00) on shares of Regenxbio in a report on Tuesday, September 5th. Zacks Investment Research raised Regenxbio from a hold rating to a strong-buy rating and set a $38.00 price target for the company in a report on Wednesday, October 18th. Morgan Stanley reaffirmed an overweight rating and set a $34.00 price target on shares of Regenxbio in a report on Thursday, November 9th. Bank of America reaffirmed a buy rating and set a $38.00 price target (up from $33.00) on shares of Regenxbio in a report on Monday, October 9th. Finally, Barclays initiated coverage on Regenxbio in a report on Wednesday, November 22nd. They set an overweight rating and a $38.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $42.43.

Shares of Regenxbio (NASDAQ RGNX) traded up $1.45 during midday trading on Thursday, reaching $31.75. The company’s stock had a trading volume of 325,700 shares, compared to its average volume of 278,419. Regenxbio has a 12 month low of $16.30 and a 12 month high of $36.10.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.04. The company had revenue of $1.34 million during the quarter. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. sell-side analysts predict that Regenxbio will post -2.71 earnings per share for the current fiscal year.

In other news, SVP Curran Simpson sold 2,000 shares of the business’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $29.31, for a total value of $58,620.00. Following the completion of the sale, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at approximately $1,216,365. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Vittal Vasista sold 5,000 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $27.39, for a total value of $136,950.00. Following the completion of the sale, the chief financial officer now directly owns 99,594 shares of the company’s stock, valued at $2,727,879.66. The disclosure for this sale can be found here. Insiders sold a total of 122,110 shares of company stock valued at $3,757,720 over the last three months. Company insiders own 17.00% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Legal & General Group Plc increased its position in Regenxbio by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 2,011 shares during the period. Ardsley Advisory Partners acquired a new position in Regenxbio in the 2nd quarter valued at about $197,000. Voya Investment Management LLC acquired a new position in Regenxbio in the 2nd quarter valued at about $249,000. Asymmetry Capital Management L.P. increased its position in Regenxbio by 12.2% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock valued at $275,000 after acquiring an additional 1,508 shares during the period. Finally, Wells Fargo & Company MN increased its position in Regenxbio by 1.1% in the 2nd quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock valued at $320,000 after acquiring an additional 175 shares during the period. 68.73% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Regenxbio (RGNX) Upgraded by BidaskClub to Buy” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/12/11/regenxbio-rgnx-upgraded-by-bidaskclub-to-buy.html.

Regenxbio Company Profile

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Stock Ratings for Regenxbio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc and related stocks with our FREE daily email newsletter.